Detection of occult lymph node metastases in locally advanced node-negative prostate cancer

Journal of Clinical Oncology

Volumn 24, Issue 18, 2006, Pages 2735-2742

  Pagliarulo, Vincenzo ^a   Hawes, Debra ^a   Brands, Frank H ^a   Groshen, Susan ^a   Cai, Jie ^a   Stein, John P ^a   Lieskovsky, Gary ^a   Skinner, Donald G ^a   Cote, Richard J ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN ANTIBODY; HORMONE; PROSTATE SPECIFIC ANTIGEN ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; PROSTATECTOMY; LYMPHADENECTOMY; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROSTATIC INTRAEPITHELIAL NEOPLASIA; SURVIVAL;

AGED; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; SURVIVAL ANALYSIS;

EID: 33745545860     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.4767     Document Type: Article

References (43)

1. Daneshmand S, Quek ML, Stein JP, et al: Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: Long-term results. J Urol 172:2252-2255, 2004
2. Walsh PC, Partin AW, Epstein Jl: Cancer control and quality of life following anatomical radical retropubic prostatectomy: Results at 10 years. J Urol 152:1831-1836, 1994
3. Bolla M, Collette L, Blank L, et al: Long-term results with immediate androgen supression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 360:103-106, 2002
4. Bolla M, Gonzalez D, Warde P, et al: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337:295-300, 1997
5. Messing EM, Manola J, Sarosdy, et al: Immediate hormonal therapy compared with observation after radical prostectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341:1781-1788, 1999
6. Epstein JI, Partin AW, Potter SR, et al: Adenocarcinoma of the prostate invading the seminal vesicle: Prognostic stratification based on pathologic parameters. Urology 56:283-288, 2000
7. Catalona WJ, Smith DS: Cancer recurrence and survival rates after anatomic radical retropubic prostectomy for prostate cancer: Intermediate term results. J Urol 160:2428-2434, 1998
8. Fleming ID, Cooper JS, Henson DE, et al: American Joint Committee on Cancer Staging Manual (5th Ed). Philadelphia, PA, Lippincott, 1997
9. Freeman JA, Esrig D, Grossfeld GD, et al: Incidence of occult lymph node metastases in pathological stage C (pT3N0) prostate cancer. J Urol 154: 474478, 1995
10. Gleason DF, Mellinger GT: Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111: 58-64, 1974
11. Carroll P: Rising PSA after radical treatment. Eur Urol 40:9-16, 2001
12. Shi S-R, Cote RJ, Chaiwun B, et al: Standardization of immunohistochemistry based on antigen retrieval techniques for routine formalin-fixed tissue sections. Appl Immunohistochem 6:89-96, 1998
13. Cote RJ, Peterson HF, Chaiwun B, et al: Role of immunohistochemical detection of lymph node metastases in the management of breast cancer. Lancet 354:896-900, 1999
14. Mantel N: Chi-square tests with one degree of freedom: Extensions of the Mantel-Haenszel procedure. Journal of the American Stastistical Association 58:690-700, 1963
15. Kaplan EL, Meier P: Nonparametric estimation form incomplete observations. J Am Stat Assoc 53:457-481, 1958
16. Miller RG: Survival Analysis. New York, NY, John Wiley & Sons, 1981, pp 51
17. Tarone RE: Tests for trend in life table analysis. Biometrika 62:679-682, 1975
18. Breslow N: Comparison of survival curves, in Buyse ME, Staquet MJ, Sylvester RJ (eds): Cancer Clinical Trials: Methods and Practices. Oxford, Great Britain, Oxford University Press, 1988, pp 398-403
19. Pike MC: Contribution to the discussion on the paper by R. Peto and J Peto, "Asymptotically efficient rank invariant procedured". Journal of the Royal Statistical Society Series A:201-203, 1972
20. Greenson JK, Isenhart CE, Rice R, et al: Identification of occult micrometastases in pericolic lymph nodes of Duke's B colorectal cancer patients using monoclonal antibodies against cytokeratin and CC49: Correlation with long-term survival. Cancer 73:563-569, 1994
21. Maehara Y, Oshiro T, Endo K, et al: Clinical significance of occult metastases in lymph nodes from patients with early gastric cancer who died of recurrence. Surgery 119:397-402, 1996
22. Cote RJ, Hawes D, Chaiwun B, et al: Detection of occult metastases in lung carcinomas: Progress and implications for lung cancer staging. J Surg Oncol 69:265-274, 1998
23. Osaki T, Oyama T, Gu CD, et al: Prognostic impact of micrometastatic tumor cells in the lymph nodes and bone marrow of patients with completely resected stage I non small cell lung cancer. J Clin Oncol 20:2930-2936, 2002
24. Izbicki JR, Hosch SB, Pichlmeier U, et al: Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. N Engl J Med 337:1188-1194, 1997
25. Cochran AJ, Wen DR, Morton DL: Occult tumor cells in the lymph nodes of patients with pathological stage I malignant melanoma: An immunohistological study. Am J Surg Pathol 12:612-618, 1988
26. Shariat SF, Roudier MP, Wilcox GE, et al: Comparison of immunohistochemistry with reverse transcriptase-PCR for the detection of micrometastatic prostate cancer in lymph nodes. Cancer Res 63:4662-4670, 2003
27. Stone NN, Stock RG, Unger P: Laparoscopic pelvic lymph node dissection for prostate cancer: Comparison of the extended and modified techniques. Clin Urol 158:1891-1894, 1997
28. Allaf ME, Palapattu GS, Track BJ, et al: Anatomical extent of lymph node dissection: Impact on men with clinically localized prostate cancer. J Urol 172:1840-1844, 2004
29. Cheng L, Zincke H, Blute ML, et al: Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer 91:66-73, 2001
30. Braun S, Vogl FD, Naume B, et al: A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353:793-802, 2005
31. Hawes D, Neville AM, Cote RJ: Detection of occult metastases in patients with breast cancer. Semin Surg Oncol 20:312-318, 2001
32. Pantel K, Cote RJ, Fodstad O: Detection and clinical importance of micrometastatic disease. J Natl Cancer Instit 91:1113-1124, 1999
33. Gao C-L, Dean RC, Pinto A, et al: Detection of circulating prostate specific antigen expressing prostatic cells in the bone marrow of radical prostatectomy patients by sensitive reverse transcriptase polymerase chain reaction. Clin Urol 161:1070-1076, 1999
34. Weckermann D, Muller P, Wawroschek F, et al: Micrometastases of bone marrow in localized prostate cancer: Correlation with established risk factors. J Clin Oncol 17:3438-3443, 1999
35. Sardi I, Moretti S, Ponchietti R, et al: The role of the detection of hematogenous micrometastasis in prostate adenocarcinoma and malignant melanoma by RT-PCR. Internatl J Molecul Med 3:417-419, 1999
36. Albers P, Ko Y, Wardelmann E, et al: Limitations of detection of bone-marrow micrometastasis in prostate carcinoma patients by CK18/PSA immunocytochemistry and PSA RT-PCR. Anticancer Res 20:2107-2111, 2000
37. Weckermann D, Muller P, Wawroschek F, et al: Disseminated cytokeratin positive tumor cells in the bone marrow of patients with prostate cancer: Detection and prognostic value. J Urol 166:699-704, 2001
38. Lilleby W, Nesland JM, Fossa SD, et al: Predictive markers and cancer prevention: The prognostic impact of cytokeratin-positive cells in bone marrow of patients with localized prostate cancer. Internatl J Cancer 103:91-96, 2002
39. Moreno JG, O'Hara SM, Gross S, et al: Changes in circulating carcinoma cells in patients with metastatic prostate cancer correlate with disease status. Urology 58:386-392, 2001
40. Hara N, Kasahara T, Kawasaki T, et al. Reverse transcriptase-polymerase chain reaction detection of prostate-specific antigen, prostate-specific membrane antigen, and prostate stem cell antigen in one milliliter of peripheral blood: Value for the staging of prostate cancer. Clin Cancer Res 8:1794-1799, 2002
41. Schmidt U, Bilkenroth U, Linne C, et al: Quantification of disseminated tumor cells in the bloodstream of patients with hormone-refractory prostate carcinoma undergoing cytotoxic chemotherapy. Internatl J Oncol 24:1393-1399, 2004
42. Gao C-L, Rawal SK, Sun L, et al: Diagnostic potential of prostate-specific antigen expressing epithelial cells in blood of prostate cancer patients. Clin Cancer Res 9:2543-2550, 2003
43. Patel K, Whelan PJ, Prescott S, et al: The use of real-time reverse transcriptase-PCR for prostate-specific antigen mRNA to discriminate between blood samples from healthy volunteers and from patients with metastatic prostate cancer. Clin Cancer Res 10: 7511-7519, 2004